Article

25 Things About Me

Author(s):

Linnea Olson

I have stage 4 lung cancer. Here are 24 other things about me.

  1. I have stage 4 lung cancer; the histology is invasive mucinous adenocarcinoma.
  2. I was diagnosed when I was 45 years old.
  3. The youngest of my three children was seven.
  4. That was 10 years ago — it will be 11 years in April (woohoo!)
  5. My first line of treatment was a lower left lobectomy followed by four rounds of adjuvant chemotherapy.
  6. Staged at 1b initially, I was hoping I’d be cured.
  7. My cancer came back almost immediately.
  8. For two years, we watched and waited as there were no other viable treatments.
  9. By June 2008, I had more than 33 tumors in my lungs and a biopsy confirmed metastatic spread.
  10. I was told I had three to five months to live.
  11. This was one week before my daughter got married.
  12. Even though EGFR-negative, I started Tarceva (erlotinib) as a last ditch effort and began to say goodbye to family.
  13. At a scan review in September, it was clear that my cancer was spreading but there was good news.
  14. My biopsy showed that I was ALK-positive and a phase 1 trial targeting ALK mutations had just opened.
  15. On October 1, 2008, I became the fourth person in the world with NSCLC to take Xalkori (crizotinib).
  16. I felt better within days of regular dosing.
  17. My scan review six weeks later showed almost complete resolution of the cancer in my lungs.
  18. I took Xalkori for three years before progression forced me to switch therapies.
  19. I enrolled on another phase 1 clinical trial for Zykadia (ceritinib/LDK378) with similar results.
  20. This time, I got 18 months out of an experimental therapy.
  21. When I came off trial, I returned to chemotherapy again for six months and then I took a break.
  22. I went almost a year without treatment (glorious!) but I was also becoming more symptomatic.
  23. In May 2014, I enrolled into my third phase 1 clinical trial for PF-006463922/lorlatinib — once again I responded.
  24. My cancer has been stable for 18 months and I feel fabulous.
  25. I can’t wait to share more of my story with the readers of CURE!
Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
1 expert is featured in this series.
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
1 expert is featured in this series.
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Related Content
Illustration of lungs.
January 11th 2025

FDA Grants Fast Track Designation for Abenacianine in Lung Cancer Surgery

Spencer Feldman
The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of red blood cells.
January 10th 2025

P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia

Ryan Scott
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Gai Terrell / Redferns via Getty Images
January 10th 2025

Peter Yarrow Dies of Bladder Cancer, Dick Vitale Cleared for ESPN Return and More

Alex Biese
From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, here is this week’s news.
Image of various gynecological cancers.
January 10th 2025

First-Line Lenvima Plus Keytruda Misses Mark in Endometrial Cancer

Alex Biese
For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve outcomes versus chemotherapy.